Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?

References

• Abe T, Takahashi M, Kano M, Amaike Y, Ishii C, Maeda K, Kudoh Y, Morishita T, Hosaka T, Sasaki T, et al. 2017. Activation of nuclear receptor CAR by an environmental pollutant perfluorooctanoic acid. Arch Toxicol. 91:2365–2374.
   PubMed Web of Science ®Google Scholar
• Adiels M, Olofsson SO, Taskinen MR, Borén J. 2008. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol. 28:1225–1236.
   PubMed Web of Science ®Google Scholar
• Ason B, van der Hoorn JWA, Chan J, Lee E, Pieterman EJ, Nguyen KK, Di M, Shetterly S, Tang J, Yeh WC, et al. 2014. PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. J Lipid Res. 55:2370–2379.
   PubMed Web of Science ®Google Scholar
• ATSDR. 2018. Toxicological profile for perfluoroalkyls. Draft for Public Comment June 2018. https://www.atsdr.cdc.gov/toxprofiles/tp200.pdf
   Google Scholar
• Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H. 1997. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes. 46:1319–1327.
   PubMed Web of Science ®Google Scholar
• Ballesteros V, Costa O, Iniguez C, Fletcher T, Ballester F, Lopez-Espinosa MJ. 2017. Exposure to perfluoroalkyl substances and thyroid function in pregnant women and children: a systematic review of epidemiologic studies. Environ Int. 99:15–28.
   PubMed Web of Science ®Google Scholar
• Bartell SM, Calafat AM, Lyu C, Kato K, Ryan PB, Steenland K. 2010. Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. Environ Health Perspect. 118:222–228.
   PubMed Web of Science ®Google Scholar
• Beesoon S, Martin JW. 2015. Isomer-specific binding affinity of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) to serum proteins. Environ Sci Technol. 49:5722–5731.
   PubMed Web of Science ®Google Scholar
• Beggs KM, McGreal SR, McCarthy A, Gunewardena S, Lampe JN, Lau C, Apte U. 2016. The role of hepatocyte nuclear factor 4-alpha in perfluorooctanoic acid- and perfluorooctanesulfonic acid-induced hepatocellular dysfunction. Toxicol Appl Pharmacol. 304:18–29.
   PubMed Web of Science ®Google Scholar
• Behr AC, Kwiatkowski A, Ståhlman M, Schmidt FF, Luckert C, Braeuning A, Buhrke T. 2020. Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells. Arch Toxicol. 94:1673–1686.
   PubMed Web of Science ®Google Scholar
• Behr AC, Plinsch C, Braeuning A, Buhrke T. 2020. Activation of human nuclear receptors by perfluoroalkylated substances (PFAS). Toxicol in Vitro. 62:104700.
   PubMed Web of Science ®Google Scholar
• Bergen WG, Mersmann HJ. 2005. Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J Nutr. 135:2499–2502.
   PubMed Web of Science ®Google Scholar
• Bijland S, Rensen PC, Pieterman EJ, Maas AC, van der Hoorn JW, van Erk MJ, Havekes LM, Willems van Dijk K, Chang SC, Ehresman DJ, et al. 2011. Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice. Toxicol Sci. 123:290–303.
   PubMed Web of Science ®Google Scholar
• Bjork JA, Butenhoff JL, Wallace KB. 2011. Multiplicity of nuclear receptor activation by PFOA and PFOS in primary human and rodent hepatocytes. Toxicology. 288:8–17.
   PubMed Web of Science ®Google Scholar
• Bjork JA, Wallace KB. 2009. Structure-activity relationships and human relevance for perfluoroalkyl acid-induced transcriptional activation of peroxisome proliferation in liver cell cultures. Toxicol Sci. 111:89–99.
   PubMed Web of Science ®Google Scholar
• Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, et al. 2020. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 41:2313–2330.
   PubMed Web of Science ®Google Scholar
• Brede E, Wilhelm M, Goen T, Muller J, Rauchfuss K, Kraft M, Holzer J. 2010. Two-year follow-up biomonitoring pilot study of residents’ and controls’ PFC plasma levels after PFOA reduction in public water system in Arnsberg, Germany. Int J Hyg Environ Health. 213:217–223.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. 1997. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 89:331–340.
   PubMed Web of Science ®Google Scholar
• Buhrke T, Krüger E, Pevny S, Rößler M, Bitter K, Lampen A. 2015. Perfluorooctanoic acid (PFOA) affects distinct molecular signalling pathways in human primary hepatocytes. Toxicology. 333:53–62.
   PubMed Web of Science ®Google Scholar
• Butenhoff J, Costa G, Elcombe C, Farrar D, Hansen K, Iwai H, Jung R, Kennedy G Jr, Lieder P, Olsen G, et al. 2002. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. Toxicol Sci. 69:244–257.
   PubMed Web of Science ®Google Scholar
• Butenhoff JL, Chang SC, Olsen GW, Thomford PJ. 2012. Chronic dietary toxicity and carcinogenicity study with potassium perfluorooctanesulfonate in Sprague Dawley rats. Toxicology. 293:1–15.
   PubMed Web of Science ®Google Scholar
• Butenhoff JL, Kennedy GL Jr, Chang SC, Olsen GW. 2012. Chronic dietary toxicity and carcinogenicity study with ammonium perfluorooctanoate in Sprague-Dawley rats. Toxicology. 298:1–13.
   PubMed Web of Science ®Google Scholar
• Butenhoff JL, Kennedy GL Jr, Hinderliter PM, Lieder PH, Jung R, Hansen KJ, Gorman GS, Noker PE, Thomford PJ. 2004. Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys. Toxicol Sci. 82:394–406.
   PubMed Web of Science ®Google Scholar
• Canova C, Barbieri G, Zare Jeddi M, Gion M, Fabricio A, Daprà F, Russo F, Fletcher T, Pitter G. 2020. Associations between perfluoroalkyl substances and lipid profile in a highly exposed young adult population in the Veneto Region. Environ Int. 145:106117.
   PubMed Web of Science ®Google Scholar
• Chamouton J, Latruffe N. 2012. PPARα/HNF4α interplay on diversified responsive elements. Relevance in the regulation of liver peroxisomal fatty acid catabolism. Curr Drug Metab. 13:1436–1453.
   PubMed Web of Science ®Google Scholar
• Chang S, Allen BC, Andres KL, Ehresman DJ, Falvo R, Provencher A, Olsen GW, Butenhoff JL. 2017. Evaluation of serum lipid, thyroid, and hepatic clinical chemistries in association with serum perfluorooctanesulfonate (PFOS) in cynomolgus monkeys after oral dosing with potassium pfos. Toxicol Sci.156:387–401.
   PubMed Web of Science ®Google Scholar
• Chang SC, Noker PE, Gorman GS, Gibson SJ, Hart JA, Ehresman DJ, Butenhoff JL. 2012. Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys. Reprod Toxicol. 33:428–440.
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Le Goff W, Guerin M, Kontush A. 2010. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J. 31:149–164.
   PubMed Web of Science ®Google Scholar
• Chen W, Owsley E, Yang Y, Stroup D, Chiang JY. 2001. Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids. J Lipid Res. 42:1402–1412.
   PubMed Web of Science ®Google Scholar
• Chiang JY. 1998. Regulation of bile acid synthesis. Front Biosci. 3:d176–193.
   PubMedGoogle Scholar
• Chiang JY. 2017. Recent advances in understanding bile acid homeostasis. F1000Res. 6:2029–2029.
   PubMedGoogle Scholar
• Convertino M, Church TR, Olsen GW, Liu Y, Doyle E, Elcombe CR, Barnett AL, Samuel LM, MacPherson IR, Evans TRJ. 2018. Stochastic Pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA). Toxicol Sci. 163:293–306.
   PubMed Web of Science ®Google Scholar
• Corton JC, Cunningham ML, Hummer BT, Lau C, Meek B, Peters JM, Popp JA, Rhomberg L, Seed J, Klaunig JE. 2014. Mode of action framework analysis for receptor-mediated toxicity: the peroxisome proliferator-activated receptor alpha (PPARα) as a case study. Crit Rev Toxicol. 44:1–49.
   PubMed Web of Science ®Google Scholar
• Curran I, Hierlihy SL, Liston V, Pantazopoulos P, Nunnikhoven A, Tittlemier S, Barker M, Trick K, Bondy G. 2008. Altered fatty acid homeostasis and related toxicologic sequelae in rats exposed to dietary potassium perfluorooctanesulfonate (PFOS). J Toxicol Environ Health A. 71:1526–1541.
   PubMed Web of Science ®Google Scholar
• Darrow LA, Stein CR, Steenland K. 2013. Serum perfluorooctanoic acid and perfluorooctane sulfonate concentrations in relation to birth outcomes in the mid-Ohio Valley, 2005–2010. Environ Health Perspect. 121:1207–1213.
   PubMed Web of Science ®Google Scholar
• Das KP, Wood CR, Lin MT, Starkov AA, Lau C, Wallace KB, Corton JC, Abbott BD. 2017. Perfluoroalkyl acids-induced liver steatosis: effects on genes controlling lipid homeostasis. Toxicology. 378:37–52.
   PubMed Web of Science ®Google Scholar
• de la Rosa Rodriguez MA, Sugahara G, Hooiveld G, Ishida Y, Tateno C, Kersten S. 2018. The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice. BMC Genomics. 19:443.
   PubMed Web of Science ®Google Scholar
• DeBose-Boyd RA. 2008. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res. 18:609–621.
   PubMed Web of Science ®Google Scholar
• DeWitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, Cunard R, Anderson SE, Meade BJ, Peden-Adams MM, et al. 2009. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha. Crit Rev Toxicol. 39:76–94.
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD, Spady DK. 1993. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 34:1637–1659.
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD. 2002. Control of cholesterol turnover in the mouse. J Biol Chem. 277:3801–3804.
   PubMed Web of Science ®Google Scholar
• DWQI. 2017. New Jersey Drinking Water Quality Institute Health Effects Subcommittee. Health-based maximum contaminant level support document: perfluorooctanoic acid (PFOA).
   Google Scholar
• DWQI. 2018. New Jersey Drinking Water Quality Institute Health Effects Subcommittee. Health-based maximum contaminant level support document: perfluorooctane sulfonate (PFOS).
   Google Scholar
• Dzierlenga AL, Robinson VG, Waidyanatha S, DeVito MJ, Eifrid MA, Gibbs ST, Granville CA, Blystone CR. 2020. Toxicokinetics of perfluorohexanoic acid (PFHxA), perfluorooctanoic acid (PFOA) and perfluorodecanoic acid (PFDA) in male and female Hsd:Sprague dawley SD rats following intravenous or gavage administration. Xenobiotica. 50:722–732.
   PubMed Web of Science ®Google Scholar
• Dzierlenga MW, Keast DR, Longnecker MP. 2020. The concentration of several perfluoroalkyl acids in serum appears to be reduced by dietary fiber. medRxiv. 2020.2007.2015.20154922.
   Google Scholar
• EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), Schrenk D, Bignami M, Bodin L, Chipman JK, del Mazo J, Grasl-Kraupp B, Hogstrand C, Hoogenboom LR, Leblanc JC, Nebbia CS, et al. 2020. Scientific Opinion on the risk to human health related to the presence of perfluoroalkyl substances in food. EFSA J. 18:6223.
   Web of Science ®Google Scholar
• EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain). Knutsen HK, Alexander J, Barregard L, Bignami M, Bruschweiler B, Ceccatelli S, Cottrill B, Dinovi M, Edler L, Grasl-Kraupp B, et al. 2018a. Scientific Opinion on the risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food. EFSA J. 16:5194.
   Web of Science ®Google Scholar
• EFSA CONTAM Panel. 2018b. Minutes of the expert meeting on perfluooroctane sulfonic acid and perfluorooctanoic acid in food assessment. https://www.efsa.europa.eu/sites/default/files/news/efsa-contam-3503.pdf
   Google Scholar
• Ehresman DJ, Froehlich JW, Olsen GW, Chang SC, Butenhoff JL. 2007. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ Res. 103:176–184.
   PubMed Web of Science ®Google Scholar
• Elcombe CR, Elcombe BM, Foster JR, Chang SC, Ehresman DJ, Butenhoff JL. 2012. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPARα and CAR/PXR. Toxicology. 293:16–29.
   PubMed Web of Science ®Google Scholar
• Ellis EC, Naugler WE, Parini P, Mörk LM, Jorns C, Zemack H, Sandblom AL, Björkhem I, Ericzon BG, Wilson EM, et al. 2013. Mice with chimeric livers are an improved model for human lipoprotein metabolism. PLoS One. 8:e78550.
   PubMed Web of Science ®Google Scholar
• Ericson I, Gómez M, Nadal M, van Bavel B, Lindström G, Domingo JL. 2007. Perfluorinated chemicals in blood of residents in Catalonia (Spain) in relation to age and gender: a pilot study. Environ Int. 33:616–623.
   PubMed Web of Science ®Google Scholar
• Eriksen KT, Raaschou-Nielsen O, McLaughlin JK, Lipworth L, Tjønneland A, Overvad K, Sørensen M. 2013. Association between plasma PFOA and PFOS levels and total cholesterol in a middle-aged Danish population. PloS One. 8:e56969.
   PubMed Web of Science ®Google Scholar
• Fabbrini E, Mohammed BS, Korenblat KM, Magkos F, McCrea J, Patterson BW, Klein S. 2010. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 95:2727–2735.
   PubMed Web of Science ®Google Scholar
• Fàbrega F, Kumar V, Schuhmacher M, Domingo JL, Nadal M. 2014. PBPK modeling for PFOS and PFOA: validation with human experimental data. Toxicol Lett. 230:244–251.
   PubMed Web of Science ®Google Scholar
• Feingold KR. 2000. Introduction to lipids and lipoproteins. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A, Hershman JM, Hofland J, Kaltsas G, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com. [Updated 2018 Feb 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK305896/
   Google Scholar
• Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. 2017. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 38:2459–2472.
   PubMed Web of Science ®Google Scholar
• Fitz-Simon N, Fletcher T, Luster MI, Steenland K, Calafat AM, Kato K, Armstrong B. 2013. Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid. Epidemiology (Cambridge, Mass). 24:569–576.
   PubMed Web of Science ®Google Scholar
• Frisbee SJ, Shankar A, Knox SS, Steenland K, Savitz DA, Fletcher T, Ducatman AM. 2010. Perfluorooctanoic acid, perfluorooctanesulfonate, and serum lipids in children and adolescents: results from the C8 Health Project. Arch Pediatr Adolesc Med. 164:860–869.
   PubMed Web of Science ®Google Scholar
• Fujii Y, Niisoe T, Harada KH, Uemoto S, Ogura Y, Takenaka K, Koizumi A. 2015. Toxicokinetics of perfluoroalkyl carboxylic acids with different carbon chain lengths in mice and humans. J Occup Health. 57:1–12.
   PubMed Web of Science ®Google Scholar
• Gallo V, Leonardi G, Genser B, Lopez-Espinosa MJ, Frisbee SJ, Karlsson L, Ducatman AM, Fletcher T. 2012. Serum perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) concentrations and liver function biomarkers in a population with elevated PFOA exposure. Environ Health Perspect. 120:655–660.
   PubMed Web of Science ®Google Scholar
• Geiger SD, Xiao J, Ducatman A, Frisbee S, Innes K, Shankar A. 2014. The association between PFOA, PFOS and serum lipid levels in adolescents. Chemosphere. 98:78–83.
   PubMed Web of Science ®Google Scholar
• Genuis SJ, Birkholz D, Ralitsch M, Thibault N. 2010. Human detoxification of perfluorinated compounds. Public Health. 124:367–375.
   PubMed Web of Science ®Google Scholar
• Genuis SJ, Curtis L, Birkholz D. 2013. Gastrointestinal elimination of perfluorinated compounds using cholestyramine and Chlorella pyrenoidosa. ISRN Toxicol. 2013:657849.
   PubMedGoogle Scholar
• Gleason JA, Post GB, Fagliano JA. 2015. Associations of perfluorinated chemical serum concentrations and biomarkers of liver function and uric acid in the US population (NHANES), 2007-2010. Environ Res. 136:8–14.
   PubMed Web of Science ®Google Scholar
• Gomis MI, Vestergren R, Borg D, Cousins IT. 2018. Comparing the toxic potency in vivo of long-chain perfluoroalkyl acids and fluorinated alternatives. Environ Int. 113:1–9.
   PubMed Web of Science ®Google Scholar
• Göttlicher M, Widmark E, Li Q, Gustafsson JA. 1992. Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA. 89:4653–4657.
   PubMed Web of Science ®Google Scholar
• Guruge KS, Yeung LW, Yamanaka N, Miyazaki S, Lam PK, Giesy JP, Jones PD, Yamashita N. 2006. Gene expression profiles in rat liver treated with perfluorooctanoic acid (PFOA). Toxicol Sci. 89:93–107.
   PubMed Web of Science ®Google Scholar
• Han X, Nabb DL, Russell MH, Kennedy GL, Rickard RW. 2012. Renal elimination of perfluorocarboxylates (PFCAs). Chem Res Toxicol. 25:35–46.
   PubMed Web of Science ®Google Scholar
• Harada KH, Hashida S, Kaneko T, Takenaka K, Minata M, Inoue K, Saito N, Koizumi A. 2007. Biliary excretion and cerebrospinal fluid partition of perfluorooctanoate and perfluorooctane sulfonate in humans. Environ Toxicol Pharmacol. 24:134–139.
   PubMed Web of Science ®Google Scholar
• Haughom B, Spydevold O. 1992. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid. Biochim Biophys Acta. 1128:65–72.
   PubMed Web of Science ®Google Scholar
• Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. 2001. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol. 21:1393–1403.
   PubMed Web of Science ®Google Scholar
• Heusinkveld HJ, Wackers PFK, Schoonen WG, van der Ven L, Pennings JLA, Luijten M. 2018. Application of the comparison approach to open TG-GATEs: a useful toxicogenomics tool for detecting modes of action in chemical risk assessment. Food Chem Toxicol. 121:115–123.
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. 2002. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 109:1125–1131.
   PubMed Web of Science ®Google Scholar
• Howroyd P, Swanson C, Dunn C, Cattley RC, Corton JC. 2004. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). Toxicol Pathol. 32:591–599.
   PubMed Web of Science ®Google Scholar
• Huang MC, Dzierlenga AL, Robinson VG, Waidyanatha S, DeVito MJ, Eifrid MA, Granville CA, Gibbs ST, Blystone CR. 2019. Toxicokinetics of perfluorobutane sulfonate (PFBS), perfluorohexane-1-sulphonic acid (PFHxS), and perfluorooctane sulfonic acid (PFOS) in male and female Hsd:Sprague Dawley SD rats after intravenous and gavage administration. Toxicol Rep. 6:645–655.
   PubMed Web of Science ®Google Scholar
• Hui Z, Li R, Chen L. 2017. The impact of exposure to environmental contaminant on hepatocellular lipid metabolism. Gene. 622:67–71.
   PubMed Web of Science ®Google Scholar
• Imes CC, Austin MA. 2013. Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics. Biol Res Nurs. 15:292–308.
   PubMed Web of Science ®Google Scholar
• Jain RB, Ducatman A. 2019. Selective associations of recent low concentrations of perfluoroalkyl substances with liver function biomarkers: NHANES 2011 to 2014 Data on US Adults Aged ≥20 Years. J Occup Environ Med. 61:293–302.
   PubMed Web of Science ®Google Scholar
• Janssen AW, Betzel B, Stoopen G, Berends FJ, Janssen IM, Peijnenburg AA, Kersten S. 2015. The impact of PPARα activation on whole genome gene expression in human precision cut liver slices. BMC Genomics. 16:760.
   PubMed Web of Science ®Google Scholar
• Jeon TI, Osborne TF. 2012. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab. 23:65–72.
   PubMed Web of Science ®Google Scholar
• Kaabia Z, Poirier J, Moughaizel M, Aguesse A, Billon-Crossouard S, Fall F, Durand M, Dagher E, Krempf M, Croyal M. 2018. Plasma lipidomic analysis reveals strong similarities between lipid fingerprints in human, hamster and mouse compared to other animal species. Sci Rep. 8:15893.
   PubMed Web of Science ®Google Scholar
• Kersten S, Stienstra R. 2017. The role and regulation of the peroxisome proliferator activated receptor alpha in human liver. Biochimie. 136:75–84.
   PubMed Web of Science ®Google Scholar
• Kersten S. 2014. Integrated physiology and systems biology of PPARα. Mol Metab. 3:354–371.
   PubMed Web of Science ®Google Scholar
• Kim NH, Kim SG. 2020. Fibrates revisited: potential role in cardiovascular risk reduction. Diabetes Metab J. 44:213–221.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Heo SH, Lee DS, Hwang IG, Lee YB, Cho HY. 2016. Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats. Food Chem Toxicol. 97:243–255.
   PubMed Web of Science ®Google Scholar
• Kir S, Zhang Y, Gerard RD, Kliewer SA, Mangelsdorf DJ. 2012. Nuclear receptors HNF4α and LRH-1 cooperate in regulating Cyp7a1 in vivo. J Biol Chem. 287:41334–41341.
   PubMed Web of Science ®Google Scholar
• Krause BR, Princen HM. 1998. Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis. 140:15–24.
   PubMed Web of Science ®Google Scholar
• Kudo N, Katakura M, Sato Y, Kawashima Y. 2002. Sex hormone-regulated renal transport of perfluorooctanoic acid. Chem Biol Interact. 139:301–316.
   PubMed Web of Science ®Google Scholar
• Kudo N, Sakai A, Mitsumoto A, Hibino Y, Tsuda T, Kawashima Y. 2007. Tissue distribution and hepatic subcellular distribution of perfluorooctanoic acid at low dose are different from those at high dose in rats. Biol Pharm Bull. 30:1535–1540.
   PubMed Web of Science ®Google Scholar
• Kühnast S, Fiocco M, van der Hoorn JW, Princen HM, Jukema JW. 2015. Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising: A systematic review and meta-analysis of relevant preclinical studies and clinical trials. Eur J Pharmacol. 763:48–63.
   PubMed Web of Science ®Google Scholar
• Kwiterovich PO. Jr. 2000. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol. 86:5l–10. l.
   PubMed Web of Science ®Google Scholar
• Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC. 2012. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 27:341–350.
   PubMed Web of Science ®Google Scholar
• Laskar MG, Eriksson M, Rudling M, Angelin B. 2017. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C–III. J. Intern. Med. 281: 575–585.
   Google Scholar
• Lee-Rueckert M, Escola-Gil JC, Kovanen PT. 2016. HDL functionality in reverse cholesterol transport – challenges in translating data emerging from mouse models to human disease. Biochim Biophys Acta. 1861:566–583.
   PubMed Web of Science ®Google Scholar
• Leritz EC, McGlinchey RE, Salat DH, Milberg WP. 2016. Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory. Metab Brain Dis. 31:465–473.
   PubMed Web of Science ®Google Scholar
• Li AC, Glass CK. 2004. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res. 45:2161–2173.
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. 2005. Mechanism of rifampicin and pregnane X receptor inhibition of human cholesterol 7 alpha-hydroxylase gene transcription. Am J Physiol Gastrointest Liver Physiol. 288:G74–84.
   PubMed Web of Science ®Google Scholar
• Li T, Chiang JY. 2009. Regulation of bile acid and cholesterol metabolism by PPARs. PPAR Res. 2009:501739.
   PubMed Web of Science ®Google Scholar
• Li Y, Barregard L, Xu Y, Scott K, Pineda D, Lindh CH, Jakobsson K, Fletcher T. 2020. Associations between perfluoroalkyl substances and serum lipids in a Swedish adult population with contaminated drinking water. Environ Health. 19:33.
   PubMed Web of Science ®Google Scholar
• Lin CY, Lin LY, Chiang CK, Wang WJ, Su YN, Hung KY, Chen PC. 2010. Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am J Gastroenterol. 105:1354–1363.
   PubMed Web of Science ®Google Scholar
• Liss KH, Finck BN. 2017. PPARs and nonalcoholic fatty liver disease. Biochimie. 136:65–74.
   PubMed Web of Science ®Google Scholar
• Lou I, Wambaugh JF, Lau C, Hanson RG Lindstrom AB, Strynar MJ, et al. (2009). Modelling single and repeated dose pharmacokinetics of PFOA in mice. Toxicol Sci. 107(2):331–341.
   Google Scholar
• Louisse J, Rijkers D, Stoopen G, Janssen A, Staats M, Hoogenboom R, Kersten S, Peijnenburg A. 2020. Perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorononanoic acid (PFNA) increase triglyceride levels and decrease cholesterogenic gene expression in human HepaRG liver cells. Arch Toxicol. 94:3137–3155.
   PubMed Web of Science ®Google Scholar
• Loveless SE, Finlay C, Everds NE, Frame SR, Gillies PJ, O'Connor JC, Powley CR, Kennedy GL. 2006. Comparative responses of rats and mice exposed to linear/branched, linear, or branched ammonium perfluorooctanoate (APFO). Toxicology. 220:203–217.
   PubMed Web of Science ®Google Scholar
• Lu H. 2016. Crosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids. Acta Pharm Sin B. 6:393–408.
   PubMed Web of Science ®Google Scholar
• Luebker DJ, Hansen KJ, Bass NM, Butenhoff JL, Seacat AM. 2002. Interactions of fluorochemicals with rat liver fatty acid-binding protein. Toxicology. 176:175–185.
   PubMed Web of Science ®Google Scholar
• Marques LR, Diniz TA, Antunes BM, Rossi FE, Caperuto EC, Lira FS, Gonçalves DC. 2018. Reverse cholesterol transport: molecular mechanisms and the non-medical approach to enhance HDL cholesterol. Front Physiol. 9:526.
   PubMed Web of Science ®Google Scholar
• McMullen PD, Bhattacharya S, Woods CG, Pendse SN, McBride MT, Soldatow VY, Deisenroth C, LeCluyse EL, Clewell RA, Andersen ME. 2020. Identifying qualitative differences in PPARα signaling networks in human and rat hepatocytes and their significance for next generation chemical risk assessment methods. Toxicol in Vitro. 64:104463.
   PubMed Web of Science ®Google Scholar
• Miao J, Fang S, Bae Y, Kemper JK. 2006. Functional inhibitory cross-talk between constitutive androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-1 and PGC-1alpha. J Biol Chem. 281:14537–14546.
   PubMed Web of Science ®Google Scholar
• Minata M, Harada KH, Kärrman A, Hitomi T, Hirosawa M, Murata M, Gonzalez FJ, Koizumi A. 2010. Role of peroxisome proliferator-activated receptor-alpha in hepatobiliary injury induced by ammonium perfluorooctanoate in mouse liver. Ind Health. 48:96–107.
   PubMed Web of Science ®Google Scholar
• Morton RE, Izem L. 2014. Cholesteryl ester transfer proteins from different species do not have equivalent activities. J Lipid Res. 55:258–265.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Terada T, Harada KH, Hitomi T, Inoue K, Inui K, Koizumi A. 2009. Human organic anion transporter hOAT4 is a transporter of perfluorooctanoic acid. Basic Clin Pharmacol Toxicol. 105:136–138.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Ramdhan DH, Tanaka N, Naito H, Tamada H, Ito Y, Li Y, Hayashi Y, Yamagishi N, Yanagiba Y, et al. 2012. Modulation of ammonium perfluorooctanoate-induced hepatic damage by genetically different PPARα in mice. Arch Toxicol. 86:63–74.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Ito Y, Yanagiba Y, Ramdhan DH, Kono Y, Naito H, Hayashi Y, Li Y, Aoyama T, Gonzalez FJ, et al. 2009. Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor alpha, but not human PPARalpha. Toxicology. 265:27–33.
   PubMed Web of Science ®Google Scholar
• Nelson JW, Hatch EE, Webster TF. 2010. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general U.S. population. Environ Health Perspect. 118:197–202.
   PubMed Web of Science ®Google Scholar
• Nian M, Li QQ, Bloom M, Qian ZM, Syberg KM, Vaughn MG, Wang SQ, Wei Q, Zeeshan M, Gurram N, et al. 2019. Liver function biomarkers disorder is associated with exposure to perfluoroalkyl acids in adults: Isomers of C8 Health Project in China. Environ Res. 172:81–88.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Varbo A. 2014. Triglycerides and cardiovascular disease. Lancet. 384:626–635.
   PubMed Web of Science ®Google Scholar
• NTP. 2019a. NTP technical report on the toxicity studies of perfluoroalkyl sulfonates (perfluorobutane sulfonic acid, perfluorohexane sulfonate potassium salt, and perfluorooctane sulfonic acid) administered by gavage to Sprague Dawley (Hsd:Sprague Dawley SD) rats. Research Triangle Park (NC): National Toxicology Program. Toxicity Report 96.
   Google Scholar
• NTP. 2019b. NTP technical report on the toxicity studies of perfluoroalkyl carboxylates (perfluorohexanoic acid, perfluorooctanoic acid, perfluorononanoic acid, and perfluorodecanoic acid) administered by gavage to Sprague Dawley (Hsd:Sprague Dawley SD) rats. Research Triangle Park (NC): National Toxicology Program. Toxicity Report 97.
   Google Scholar
• Numata J, Kowalczyk J, Adolphs J, Ehlers S, Schafft H, Fuerst P, Muller-Graf C, Lahrssen-Wiederholt M, Greiner M. 2014. Toxicokinetics of seven perfluoroalkyl sulfonic and carboxylic acids in pigs fed a contaminated diet. J Agric Food Chem. 62:6861–6870.
   PubMed Web of Science ®Google Scholar
• OECD. 2015. Risk reduction approaches for PFASS – a crosscountry analysis. Paris (France): OECD.
   Google Scholar
• Okyere J, Oppon E, Dzidzienyo D, Sharma L, Ball G. 2014. Cross-species gene expression analysis of species specific differences in the preclinical assessment of pharmaceutical compounds. PLoS One. 9:e96853.
   PubMed Web of Science ®Google Scholar
• Olsen GW, Burris JM, Burlew MM, Mandel JH. 2003. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med. 45:260–270.
   PubMed Web of Science ®Google Scholar
• Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, Zobel LR. 2007. Half-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 115:1298–1305.
   PubMed Web of Science ®Google Scholar
• Olsen GW, Hansen KJ, Stevenson LA, Burris JM, Mandel JH. 2003. Human donor liver and serum concentrations of perfluorooctanesulfonate and other perfluorochemicals. Environ Sci Technol. 37:888–891.
   PubMed Web of Science ®Google Scholar
• Olsen GW, Zobel LR. 2007. Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. Int Arch Occup Environ Health. 81:231–246.
   PubMed Web of Science ®Google Scholar
• Ory DS. 2004. Nuclear receptor signaling in the control of cholesterol homeostasis: have the orphans found a home? Circ Res. 95:660–670.
   PubMed Web of Science ®Google Scholar
• Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. 1998. Peroxisome proliferator activated receptor-alpha expression in human liver. Mol Pharmacol. 53:14–22.
   PubMed Web of Science ®Google Scholar
• Papazyan R, Liu X, Liu J, Dong B, Plummer EM, Lewis RD 2nd, Roth JD, Young MA. 2018. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver. J Lipid Res. 59:982–993.
   PubMed Web of Science ®Google Scholar
• Pawlak M, Lefebvre P, Staels B. 2015. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 62:720–733.
   PubMed Web of Science ®Google Scholar
• Peng S, Yan L, Zhang J, Wang Z, Tian M, Shen H. 2013. An integrated metabonomics and transcriptomics approach to understanding metabolic pathway disturbance induced by perfluorooctanoic acid. J Pharm Biomed Anal. 86:56–64.
   PubMed Web of Science ®Google Scholar
• Perez F, Nadal M, Navarro-Ortega A, Fabrega F, Domingo JL, Barcelo D, Farre M. 2013. Accumulation of perfluoroalkyl substances in human tissues. Environ Int. 59:354–362.
   PubMed Web of Science ®Google Scholar
• Perkins RG, Butenhoff JL, Kennedy GL Jr, Palazzolo MJ. 2004. 13-Week dietary toxicity study of ammonium perfluorooctanoate (APFO) in male rats. Drug Chem Toxicol. 27:361–378.
   PubMed Web of Science ®Google Scholar
• Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, et al., ESC Scientific Document Group. 2016. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 37:2315–2381.
   PubMed Web of Science ®Google Scholar
• Pizzurro DM, Seeley M, Kerper LE, Beck BD. 2019. Interspecies differences in perfluoroalkyl substances (PFAS) toxicokinetics and application to health-based criteria. Regul Toxicol Pharmacol. 106:239–250.
   PubMed Web of Science ®Google Scholar
• Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. 2001. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 21:1840–1845.
   PubMed Web of Science ®Google Scholar
• Pouwer MG, Pieterman EJ, Chang SC, Olsen GW, Caspers MPM, Verschuren L, Jukema JW, Princen HMG. 2019. Dose effects of ammonium perfluorooctanoate on lipoprotein metabolism in APOE*3-Leiden.CETP Mice. Toxicol Sci. 168:519–534.
   PubMed Web of Science ®Google Scholar
• Pouwer MG, Pieterman EJ, Worms N, Keijzer N, Jukema JW, Gromada J, Gusarova V, Princen HMG. 2020. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. J Lipid Res. 61:365–375.
   PubMed Web of Science ®Google Scholar
• Princen H, Post S, Twisk J. 1997. Regulation of bile acid biosynthesis. Curr Pharm Des. 3:59–84.
   Web of Science ®Google Scholar
• Princen HMG, Pouwer MG, Pieterman EJ. 2016. Comment on "Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice" by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46–54. Toxicol Rep. 3:306–309.
   PubMed Web of Science ®Google Scholar
• Rebholz SL, Jones T, Herrick RL, Xie C, Calafat AM, Pinney SM, Woollett LA. 2016. Hypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of mice. Toxicol Rep. 3:46–54.
   PubMed Web of Science ®Google Scholar
• Ren H, Vallanat B, Nelson DM, Yeung LWY, Guruge KS, Lam PKS, Lehman-McKeeman LD, Corton JC. 2009. Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species. Reprod Toxicol. 27:266–277.
   PubMed Web of Science ®Google Scholar
• RIVM. 2018. Mixture exposure to PFAS: a relative potency factor approach. Bilthoven (The Netherlands): National Institute for Public Health and the Environment. RIVM Report 2018-0070.
   Google Scholar
• Rosen MB, Abbott BD, Wolf DC, Corton JC, Wood CR, Schmid JE, Das KP, Zehr RD, Blair ET, Lau C. 2008. Gene profiling in the livers of wild-type and PPARalpha-null mice exposed to perfluorooctanoic acid. Toxicol Pathol. 36:592–607.
   PubMed Web of Science ®Google Scholar
• Rosen MB, Das KP, Rooney J, Abbott B, Lau C, Corton JC. 2017. PPARα-independent transcriptional targets of perfluoroalkyl acids revealed by transcript profiling. Toxicology. 387:95–107.
   PubMed Web of Science ®Google Scholar
• Rosen MB, Lee JS, Ren H, Vallanat B, Liu J, Waalkes MP, Abbott BD, Lau C, Corton JC. 2008. Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR alpha and CAR. Toxicol Sci. 103:46–56.
   PubMed Web of Science ®Google Scholar
• Rosen MB, Schmid JR, Corton JC, Zehr RD, Das KP, Abbott BD, Lau C. 2010. Gene Expression Profiling in Wild-Type and PPARα-Null Mice Exposed to Perfluorooctane Sulfonate Reveals PPARα-Independent Effects. PPAR Res. 2010:1–23.
   Web of Science ®Google Scholar
• Rosenmai AK, Ahrens L, Le Godec T, Lundqvist J, Oskarsson A. 2018. Relationship between peroxisome proliferator-activated receptor alpha activity and cellular concentration of 14 perfluoroalkyl substances in HepG2 cells. J Appl Toxicol. 38:219–226.
   PubMed Web of Science ®Google Scholar
• Sakr CJ, Kreckmann KH, Green JW, Gillies PJ, Reynolds JL, Leonard RC. 2007a. Cross-sectional study of lipids and liver enzymes related to a serum biomarker of exposure (ammonium perfluorooctanoate or APFO) as part of a general health survey in a cohort of occupationally exposed workers. J Occup Environ Med. 49:1086–1096.
   PubMed Web of Science ®Google Scholar
• Sakr CJ, Leonard RC, Kreckmann KH, Slade MD, Cullen MR. 2007b. Longitudinal study of serum lipids and liver enzymes in workers with occupational exposure to ammonium perfluorooctanoate. J Occup Environ Med. 49:872–879.
   PubMed Web of Science ®Google Scholar
• Salihovic S, Stubleski J, Kärrman A, Larsson A, Fall T, Lind L, Lind PM. 2018. Changes in markers of liver function in relation to changes in perfluoroalkyl substances – a longitudinal study. Environ Int. 117:196–203.
   PubMed Web of Science ®Google Scholar
• Sandesara PB, Virani SS, Fazio S, Shapiro MD. 2019. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocr Rev. 40:537–557.
   PubMed Web of Science ®Google Scholar
• Scharmach E, Buhrke T, Lichtenstein D, Lampen A. 2012. Perfluorooctanoic acid affects the activity of the hepatocyte nuclear factor 4 alpha (HNF4α). Toxicol Lett. 212:106–112.
   PubMed Web of Science ®Google Scholar
• Schlezinger J, Puckett H, Oliver J, Nielsen G, Heiger-Bernays W, Webster T. 2020. Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an American diet. bioRxiv. 2020.2001.2030.926642
   Google Scholar
• Schoonjans K, Staels B, Auwerx J. 1996. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 37:907–925.
   PubMed Web of Science ®Google Scholar
• Seacat AM, Thomford PJ, Hansen KJ, Clemen LA, Eldridge SR, Elcombe CR, Butenhoff JL. 2003. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology. 183:117–131.
   PubMed Web of Science ®Google Scholar
• Seacat AM, Thomford PJ, Hansen KJ, Olsen GW, Case MT, Butenhoff JL. 2002. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci. 68:249–264.
   PubMed Web of Science ®Google Scholar
• Shao W, Espenshade PJ. 2012. Expanding roles for SREBP in metabolism. Cell Metab. 16:414–419.
   PubMed Web of Science ®Google Scholar
• Son HY, Kim SH, Shin HI, Bae HI, Yang JH. 2008. Perfluorooctanoic acid-induced hepatic toxicity following 21-day oral exposure in mice. Arch Toxicol. 82:239–246.
   PubMed Web of Science ®Google Scholar
• Starling AP, Engel SM, Whitworth KW, Richardson DB, Stuebe AM, Daniels JL, Haug LS, Eggesbø M, Becher G, Sabaredzovic A, et al. 2014. Perfluoroalkyl substances and lipid concentrations in plasma during pregnancy among women in the Norwegian Mother and Child Cohort Study. Environ Int. 62:104–112.
   PubMed Web of Science ®Google Scholar
• Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. 2009. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. Am J Epidemiol. 170:1268–1278.
   PubMed Web of Science ®Google Scholar
• Takacs ML, Abbott BD. 2007. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol Sci. 95:108–117.
   PubMed Web of Science ®Google Scholar
• Tan X, Xie G, Sun X, Li Q, Zhong W, Qiao P, Sun X, Jia W, Zhou Z. 2013. High fat diet feeding exaggerates perfluorooctanoic acid-induced liver injury in mice via modulating multiple metabolic pathways. PLoS One. 8:e61409.
   PubMed Web of Science ®Google Scholar
• Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. 2004. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol. 165:901–912.
   PubMed Web of Science ®Google Scholar
• Thompson MB. 1996. Bile acids in the assessment of hepatocellular function. Toxicol Pathol. 24:62–71.
   PubMed Web of Science ®Google Scholar
• Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ. 1996. Peroxisome proliferator-activated receptors: structures and function. Ann N Y Acad Sci. 804:252–265.
   PubMed Web of Science ®Google Scholar
• US EPA. 2016a. Drinking Water Health Advisory for Perfluorooctanoic Acid (PFOA). Washington (DC): US EPA Office of Water (4304T) Health and Ecological Criteria Division. EPA Document Number: 822-R-16-005.
   Google Scholar
• US EPA. 2016b. Drinking Water Health Advisory for Perfluorooctane Sulfonate (PFOS). Washington (DC): US EPA Office of Water (4304T) Health and Ecological Criteria Division. EPA Document Number: 822-R-16-004.
   Google Scholar
• Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. 2006. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol Sci. 92:476–489.
   PubMed Web of Science ®Google Scholar
• Wan HT, Zhao YG, Wei X, Hui KY, Giesy JP, Wong CK. 2012. PFOS-induced hepatic steatosis, the mechanistic actions on β-oxidation and lipid transport. Biochim Biophys Acta. 1820:1092–1101.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Y, Liang Y, Li J, Liu Y, Zhang J, Zhang A, Fu J, Jiang G. 2013. Specific accumulation of lipid droplets in hepatocyte nuclei of PFOA-exposed BALB/c mice. Sci Rep. 3:2174.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Y, Liang Y, Li J, Liu Y, Zhang J, Zhang A, Fu J, Jiang G. 2014. PFOS induced lipid metabolism disturbances in BALB/c mice through inhibition of low density lipoproteins excretion. Sci Rep. 4:4582.
   PubMed Web of Science ®Google Scholar
• Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC. 2006. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE*3-Leiden mice. ATVB. 26:2552–2559.
   Google Scholar
• Wigger L, Casals-Casas C, Baruchet M, Trang KB, Pradervand S, Naldi A, Desvergne B. 2019. System analysis of cross-talk between nuclear receptors reveals an opposite regulation of the cell cycle by LXR and FXR in human HepaRG liver cells. PLoS One. 14:e0220894.
   PubMed Web of Science ®Google Scholar
• Winquist A, Steenland K. 2014. Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. Environ Health Perspect. 122:1299–1305.
   PubMed Web of Science ®Google Scholar
• Wolf CJ, Rider CV, Lau C, Abbott BD. 2014. Evaluating the additivity of perfluoroalkyl acids in binary combinations on peroxisome proliferator-activated receptor-α activation. Toxicology. 316:43–54.
   PubMed Web of Science ®Google Scholar
• Wolf CJ, Schmid JE, Lau C, Abbott BD. 2012. Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPARα) by perfluoroalkyl acids (PFAAs): further investigation of C4-C12 compounds. Reprod Toxicol. 33:546–551.
   PubMed Web of Science ®Google Scholar
• Wolf CJ, Takacs ML, Schmid JE, Lau C, Abbott BD. 2008. Activation of mouse and human peroxisome proliferator-activated receptor alpha by perfluoroalkyl acids of different functional groups and chain lengths. Toxicol Sci. 106:162–171.
   PubMed Web of Science ®Google Scholar
• Woodcroft MW, Ellis DA, Rafferty SP, Burns DC, March RE, Stock NL, Trumpour KS, Yee J, Munro K. 2010. Experimental characterization of the mechanism of perfluorocarboxylic acids’ liver protein bioaccumulation: the key role of the neutral species. Environ Toxicol Chem. 29:1669–1677.
   PubMed Web of Science ®Google Scholar
• Wu X, Xie G, Xu X, Wu W, Yang B. 2018. Adverse bioeffect of perfluorooctanoic acid on liver metabolic function in mice. Environ Sci Pollut Res Int. 25:4787–4793.
   PubMed Web of Science ®Google Scholar
• Yan J, Chen B, Lu J, Xie W. 2015. Deciphering the roles of the constitutive androstane receptor in energy metabolism. Acta Pharmacol Sin. 36:62–70.
   PubMed Web of Science ®Google Scholar
• Yan S, Wang J, Dai J. 2015. Activation of sterol regulatory element-binding proteins in mice exposed to perfluorooctanoic acid for 28 days. Arch Toxicol. 89:1569–1578.
   PubMed Web of Science ®Google Scholar
• Yang CH, Glover KP, Han X. 2009. Organic anion transporting polypeptide (Oatp) 1a1-mediated perfluorooctanoate transport and evidence for a renal reabsorption mechanism of Oatp1a1 in renal elimination of perfluorocarboxylates in rats. Toxicol Lett. 190:163–171.
   PubMed Web of Science ®Google Scholar
• Yeh MM, Bosch DE, Daoud SS. 2019. Role of hepatocyte nuclear factor 4-alpha in gastrointestinal and liver diseases. World J Gastroenterol. 25:4074–4091.
   PubMed Web of Science ®Google Scholar
• Yin L, Ma H, Ge X, Edwards PA, Zhang Y. 2011. Hepatic hepatocyte nuclear factor 4α is essential for maintaining triglyceride and cholesterol homeostasis. Arterioscler Thromb Vasc Biol. 31:328–336.
   PubMed Web of Science ®Google Scholar
• Yu WG, Liu W, Jin YH. 2009. Effects of perfluorooctane sulfonate on rat thyroid hormone biosynthesis and metabolism. Environ Toxicol Chem. 28:990–996.
   PubMed Web of Science ®Google Scholar
• Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T. 2007. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 27:1706–1721.
   PubMed Web of Science ®Google Scholar
• Zhang H, Temel RE, Martel C. 2014. Cholesterol and lipoprotein metabolism: Early Career Committee contribution. Arterioscler Thromb Vasc Biol. 34:1791–1794.
   PubMed Web of Science ®Google Scholar
• Zhang YM, Dong XY, Fan LJ, Zhang ZL, Wang Q, Jiang N, Yang XS. 2017. Poly- and perfluorinated compounds activate human pregnane X receptor. Toxicology. 380:23–29.
   PubMed Web of Science ®Google Scholar
• Zhao W, Zitzow JD, Ehresman DJ, Chang SC, Butenhoff JL, Forster J, Hagenbuch B. 2015. Na+/Taurocholate cotransporting polypeptide and apical sodium-dependent bile acid transporter are involved in the disposition of perfluoroalkyl sulfonates in humans and rats. Toxicol Sci. 146:363–373.
   PubMed Web of Science ®Google Scholar
• Zhao W, Zitzow JD, Weaver Y, Ehresman DJ, Chang SC, Butenhoff JL, Hagenbuch B. 2017. Organic anion transporting polypeptides contribute to the disposition of perfluoroalkyl acids in humans and rats. Toxicol Sci. 156:84–95.
   PubMed Web of Science ®Google Scholar